Comparative Pharmacology
Head-to-head clinical analysis: METOCURINE IODIDE versus ROCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOCURINE IODIDE versus ROCURONIUM BROMIDE.
METOCURINE IODIDE vs ROCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting muscle contraction.
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
0.6 mg/kg IV bolus for intubation; maintenance: 0.1-0.2 mg/kg IV bolus as needed or continuous infusion 5-10 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Terminal elimination half-life: 1.4-2.4 minutes (distribution half-life: 3-5 minutes); recovery index (25-75%): 12-16 minutes; clinical duration (dose-dependent): 30-45 minutes (0.6 mg/kg) to 70-90 minutes (1.2 mg/kg)
Renal: 85-90% unchanged; biliary/fecal: <5%.
Renal: 33% unchanged; Biliary/fecal: 33% (as parent and metabolite); Hepatic metabolism: ~10-20%; remainder: unknown
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker